Hepatitis C drug spending nearly doubles in 2015

The number of patients receiving Hepatitus C treatment is on a substantial upward trend, as is the overall cost of the drugs provided to treat the liver ailment, according to an article by ProPublica’s Charles Ornstein posted on www.washingtonpost.com. 2015 drug expenditures are in the $4.8 billion range for the first half of the year compared to $4.6 billion for 2014 in total. Read the Ornstein article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; socialsecurityreport.org cannot guarantee the duration of the link’s 
validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.